Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004

M Hickman, V Hope, T Brady, P Madden, S Jones, S Honor, G Holloway, F Ncube, JV Parry

Research output: Contribution to journalArticle (Academic Journal)peer-review

79 Citations (Scopus)

Abstract

Summary. We sought to corroborate geographical differences in hepatitis C virus (HCV) prevalence and assess whether these can be explained by differences in injecting risk behaviour. A community recruited interview survey of 1058 injecting drug users (IDU) – including a blood spot specimen for antibody testing – was undertaken in seven cities in England. HCV prevalence varied from 27% to 74% across sites (χ2(6) = 115.3, P <0.001). There was a significant variation in crack-injection, prison history, injecting frequency, homelessness, groin injecting, syringe reuse and sharing between the sites. Adjustment for clustering by site and other covariates attenuated the odds ratios (OR) for most variables: e.g. crack injection changed from an unadjusted OR of >2 to an adjusted OR of 1.4 (95% CI 0.9–2.0). Remaining significant covariates included: homelessness (OR 2.2; 1.4–3.6); ever imprisonment (OR 1.7; 1.2–2.5); syringe sharing >18 months ago (OR 2.0; 1.3–3.0); injecting duration and age. Introducing site as a second level variable did not reach significance (P = 0.10). HCV prevalence among IDU reporting 'never sharing' was 48%. Geographical variation in HCV prevalence remains poorly explained, but should be the key focus of our surveillance effort. Measures of sharing and their interpretation require greater scrutiny.
Translated title of the contributionHepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004
Original languageEnglish
Pages (from-to)645 - 652
Number of pages8
JournalJournal of Viral Hepatitis
Volume14
DOIs
Publication statusPublished - Sep 2007

Bibliographical note

Publisher: Wiley InterScience

Fingerprint

Dive into the research topics of 'Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004'. Together they form a unique fingerprint.

Cite this